Adamas Pharmaceuticals (ADMS) Sets New 1-Year Low at $16.03

Adamas Pharmaceuticals Inc (NASDAQ:ADMS)’s share price hit a new 52-week low on Tuesday . The stock traded as low as $16.03 and last traded at $15.57, with a volume of 11723 shares changing hands. The stock had previously closed at $16.59.

Several equities research analysts have issued reports on the company. HC Wainwright assumed coverage on Adamas Pharmaceuticals in a research report on Monday, July 16th. They set a “buy” rating and a $45.00 target price on the stock. BidaskClub upgraded Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 17th. Mizuho restated a “buy” rating and set a $75.00 target price on shares of Adamas Pharmaceuticals in a research report on Friday, August 17th. ValuEngine downgraded Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 28th. Finally, Bank of America downgraded Adamas Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $36.00 to $25.00 in a research report on Friday, October 5th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $44.78.

The stock has a market capitalization of $467.68 million, a PE ratio of -3.98 and a beta of 1.39. The company has a quick ratio of 9.74, a current ratio of 9.92 and a debt-to-equity ratio of 0.78.



Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Thursday, August 2nd. The specialty pharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.15. Adamas Pharmaceuticals had a negative return on equity of 104.86% and a negative net margin of 1,138.59%. The company had revenue of $7.57 million for the quarter, compared to the consensus estimate of $4.84 million. As a group, analysts forecast that Adamas Pharmaceuticals Inc will post -5.37 earnings per share for the current fiscal year.

In related news, CFO Alfred G. Merriweather sold 1,665 shares of the stock in a transaction on Friday, September 21st. The stock was sold at an average price of $19.18, for a total value of $31,934.70. Following the sale, the chief financial officer now owns 25,460 shares in the company, valued at $488,322.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 24.60% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its position in Adamas Pharmaceuticals by 24.3% during the second quarter. BlackRock Inc. now owns 1,846,096 shares of the specialty pharmaceutical company’s stock valued at $47,684,000 after purchasing an additional 361,303 shares in the last quarter. Millennium Management LLC raised its position in Adamas Pharmaceuticals by 318.2% during the second quarter. Millennium Management LLC now owns 342,180 shares of the specialty pharmaceutical company’s stock valued at $8,839,000 after purchasing an additional 260,360 shares in the last quarter. Point72 Asset Management L.P. raised its position in Adamas Pharmaceuticals by 11.6% during the second quarter. Point72 Asset Management L.P. now owns 2,272,115 shares of the specialty pharmaceutical company’s stock valued at $58,689,000 after purchasing an additional 235,515 shares in the last quarter. UBS Group AG raised its position in Adamas Pharmaceuticals by 399.4% during the first quarter. UBS Group AG now owns 194,503 shares of the specialty pharmaceutical company’s stock valued at $4,649,000 after purchasing an additional 155,559 shares in the last quarter. Finally, Macquarie Group Ltd. raised its position in Adamas Pharmaceuticals by 12.5% during the second quarter. Macquarie Group Ltd. now owns 1,310,310 shares of the specialty pharmaceutical company’s stock valued at $33,846,000 after purchasing an additional 145,412 shares in the last quarter. Institutional investors own 95.23% of the company’s stock.

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply